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Introduction
An estimated 22 million people are living with HIV in 
sub-Saharan Africa [1]. Some will die as a result of their 
infections, but those who survive will need to be main-
tained on treatment at an annual per capita cost of 
approxi mately US$1500, or a total of US$660 billion over 
20 years, although costs are likely to decline in future 
[2,3]. Even if they are left to die untreated, they will still 
need healthcare before they die and the cost of treating 
their AIDS-related illnesses in sub-Saharan Africa may 
run to about US$5000 per person [4] or about US$110 
billion in total. Furthermore, each year there are more 
than twice as many new infections as there are people 
starting antiretroviral therapy (ART) [5]. While many 
lives have been saved using ART, the current situation is 
not ﬁ nancially sustainable and ways must be found to 
bring the epidemic to an end.
For long-term control of the HIV epidemic, the perti-
nent question is this: how can we stop HIV transmission? 
Many viral diseases can be prevented by vaccination, but 
for the AIDS retrovirus, the prospect of an eﬀ ective 
vaccine remains elusive [6-8]. Abstaining from sex gives 
complete protection, but behaviour change programmes 
have had limited success [9,10]. Th e evidence that 
treating sexually transmitted infections reduces HIV 
incidence remains equivocal [11]. While male circum-
cision has been shown to be eﬃ  cacious and is now being 
made available in much of Africa [12], it reduces the risk 
of HIV-infection by about 60% and only in men [13]. 
Condoms are eﬀ ective, if used consistently and correctly, 
and promoting condoms among sex workers has yielded 
positive results [14], but condom use remains limited 
[15]. Vaginal microbicides [16-18] and pre-exposure 
prophylaxis [19] both give about 50% protection to un-
infected people, but are most useful only in those at 
particularly high risk.
For those who start ART early, are fully compliant and 
have access to the best possible drug regimens, these 
drugs can reduce a person’s viral load by ﬁ ve orders of 
magnitude [20,21], dramatically reducing their infec-
tious ness to others [22-26], and keeping their viral loads 
at very low levels for years and possibly for decades 
[20,21]. Where it is available, antiretroviral treatment has 
reduced mortality rates, but has not signiﬁ cantly reduced 
community-level sexual transmission because ART is 
provided mainly in the late stages of infection [27].
Using HIV treatment as prevention (TasP), in combi-
nation with other methods of prevention that have been 
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shown to work, including male circumcision, vaginal 
microbicides and pre-exposure prophylaxis [19,28,29], 
oﬀ ers the possibility of rapidly reducing HIV trans-
mission. In this paper, we explore some operational 
research issues that need to be addressed as a matter of 
urgency if we are to consider using treatment as the 
primary means of stopping transmission and potentially 
ending the epidemic with a focus on heterosexual 
transmission in generalized epidemics.
Discussion
Treatment as prevention
Evidence supporting TasP has been outlined in a number 
of papers [3,30-32]; the arguments against using it have 
generally been concerned with practical issues of imple-
men tation, including stigma, acceptability, compliance, 
side eﬀ ects, viral load suppression, viral rebound, treat-
ment failure and drug resistance [33-36]. To these, we 
may add the importance of ensuring that a reliable and 
sustainable drug supply chain is in place, that the tools 
for monitoring the impact of TasP on both individual 
patients and the population are available, and that the 
short- and long-term costs of using TasP can be met [3].
Public health policy should be based on proven 
strategies, and amassing a body of evidence to support a 
new strategy is the necessary ﬁ rst step. Mathematical 
models, based on such data, can then provide support for 
pursuing the idea and can be used to explore alternative 
strategies, identify potential obstacles and design trials 
[3,17,37,38]. Field trials can then be carried out to 
establish the feasibility, or proof of concept, under 
realistic conditions, and to demonstrate impact at an 
individual level [25]. If possible, and only if appropriate 
and ethically acceptable, the ﬁ nal step is to carry out 
community randomized controlled trials to demonstrate 
the population-level impact directly.
Randomized controlled trials are the gold standard for 
testing new health interventions. However, a trial of TasP 
would need community, not individual, randomization, 
with the outcome being the incidence of infection. Trials 
of this kind can and have been done, but they typically 
require about six or more pairs of well-matched 
communities [39,40]. With an assumed HIV incidence of, 
say, 1% to 2% per total population per year, they require 
about 10,000 or more people in each community to 
measure a reduction in incidence of about 50%. Th e 
logistics and costs of running such a trial are substantial, 
and a trial of this kind is likely to take at least ﬁ ve years 
from start to ﬁ nish. If places can be found where baseline 
demographic and HIV trend data are available, and if the 
funding can be found, community randomized controlled 
trials should be encouraged. When that time comes, it 
will be necessary to ask if there is still equipoise con-
cerning the potential beneﬁ ts to individuals of early 
treatment as this will determine whether or not such a 
trial is ethical.
More immediately, and perhaps of more practical 
relevance, feasibility or proof-of-concept studies could be 
started almost immediately and would provide valuable 
insights and lessons concerning the eﬃ  cacy of a control 
strategy based on TasP. Th e sine qua non for the long-term 
success of this strategy will be to create community 
ownership, and to ensure that people understand that HIV 
can become a manageable chronic disease, that with ART 
they can live normal, healthy lives while being much less 
likely to infect their partners, and that eventually, this 
could eliminate new HIV infections from their community.
Th e primary goal of feasibility or proof-of-concept 
studies would be to show that it is possible to stop new 
HIV infections, whether sexually or vertically trans mit-
ted, through regular HIV testing and immediate 
provision of ART in a deﬁ ned community.
However, a number of operational challenges would 
need to be met, and key questions to be answered would 
include: 1) Will the approach be acceptable to commu-
nities where it is oﬀ ered? Can it reduce stigma and 
discrimination? 2) Will people agree to be tested annually 
for HIV? How best can this be achieved? 3) Will HIV-
positive people agree to start ART at a very early stage of 
infection? 4) Will there be signiﬁ cant side eﬀ ects? 5) If so, 
will this reduce compliance? 6) Will treatment lead to 
good viral load suppression? 7) Does good viral load 
suppression eliminate transmission? 8) Will making ART 
very widely available increase or decrease the extent to 
which people engage in risky sexual behaviour? 9) Will 
there be increases in either acquired or transmitted drug 
resistance? 11) Will it be possible to maintain people on 
treat ment in communities with frequent in and out 
migra tion? 12) Is it aﬀ ordable and can the costs be signiﬁ -
cantly reduced by relying on community support and 
engagement? 13) Will it be possible to use a substantial 
public health intervention, such as this, to create jobs in 
poor communities? 14) Can the medical infrastructure 
be ramped up quickly to deal with all the new patients on 
ART? 15) Can social media be used to communicate the 
beneﬁ ts of treatment?
Ideally, independent proof-of-concept studies to explore 
the use of TasP should be carried out in several 
communities with diﬀ erent geographical, social, demo-
graphic and epidemiological characteristics. In the worst-
aﬀ ected countries in southern and east Africa, up to 10% 
of the entire population may be infected with HIV. In a 
community of 50,000 people, about 5000 will be HIV 
positive and about 500 more people will be infected each 
year. Testing 50,000 people a year is feasible (Submitted; 
Granich R et al: Achieving Universal Access for HIV and 
TB: potential prevention impact of an integrated multi-
disease prevention campaign in Kenya), but maintaining 
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5000 people on ART at a cost of about US$1000 per person 
per year would cost US$5 million per year. If one considers 
a study lasting for two to three years and if one includes 
the cost of managing the study, as well as of the necessary 
monitoring and evaluation, the total cost would be of the 
order of US$20 million or more.
Since the success of TasP depends on achieving high 
rates of coverage and low rates of drop out, the target 
might be to ensure that fewer than about 5% drop out 
each year. With 5000 people on ART, a 5% rate can be 
measured with a precision of about 0.6%. Assuming that 
mortality in the cohort is less than 1.0% per year, this 
could be measured with a precision of 0.3%. If half the 
HIV-positive people have a regular partner and about 
half of infected couples are discordant, there will be 
about 800 discordant couples. In discordant couples not 
on ART, the transmission rate is typically about 5% per 
year [22-24], so that one would expect between 40 and 80 
infections per year. If, as anticipated, ART reduces trans-
mission by 95%, the number of transmissions in 
discordant couple should fall to between 2% and 4% per 
year, a diﬀ erence that could be measured.
Operational challenges
Th e four key strategies underlying such a trial would be: 
community empowerment, HIV testing, ART provision, 
and monitoring and evaluation. Each strategy involves 
important operational challenges that would need to be 
met.
Com munity empowerment
Unless the people living in the aﬀ ected communities have 
a sense of ownership of the project, it is unlikely to 
succeed and to be sustained. To help to achieve this, 
“gate-keepers” in the community would have to be 
identiﬁ ed, community forums would have to be estab-
lished, and representatives of young people, school teachers 
and principals, and religious and political leaders would 
have to be engaged. As far as possible, community 
members should be used to support clinical care, treat-
ment, monitoring and evaluation, and to tackle stigma 
and discrimination [41].
Monitoring systems would be needed to evaluate 
people’s understanding of HIV. Indicators would be 
needed to measure acceptance of HIV testing, enrolment 
on ART, communication among couples about HIV 
status, percentage of couples tested, decreases in high-
risk behaviour, increases in male circumcision, earlier 
engagement into HIV treatment services for HIV-
positive people, especially pregnant women and tubercu-
losis patients, and male involvement.
Individual incentives for members of the community 
performing tasks integral to the ultimate success of TasP 
should be provided, but incentives should be tiered and 
based on performance goals measured through the 
community monitoring systems and indicators.
HIV testing
Since the beginning of 2004, HIV tests have been oﬀ ered 
as a routine part of checkups in public and private clinics 
in Botswana [42] and could be complemented with 
regular testing campaigns. Data collected in the testing 
process would be used to determine the HIV incidence 
and to monitor changes over time. All testing should 
result in referral to appropriate HIV services, such as 
male circumcision, HIV prevention, risk reduction, 
family planning, and ART for HIV-positive people. 
Ideally, all those at risk of HIV in the community, 
including children exposed to mother to child trans mis-
sion, should be tested within the ﬁ rst year. HIV-negative 
people may be scheduled for retesting after three months 
and then annually. During the ﬁ rst year, pooled plasma 
RNA sampling of HIV negative cases can be used to 
provide estimates of acute infection rates in the 
community, providing the opportunity to determine 
whether this is a signiﬁ cant driver of new infections 
requiring particular attention.
ART provision
HIV-positive patients will have to be referred for 
immediate counselling, evaluation and initiation on ART, 
regardless of CD4 count or clinical staging. If ﬁ nancial 
and human resources are limited, one could consider 
giving priority to those with high viral loads as they have 
the shortest survival [43,44] and are the most infectious 
to others [22-24]. Patients on ART must be monitored for 
toxicity and side eﬀ ects of ART. Routine samples will be 
collected to evaluate HIV resistance, viral load and CD4+ 
cell counts. Viral load monitoring is critical for testing 
the impact of TasP and should be carried out six weeks 
after ART initiation and then every six months for people 
on ART.
Expanded training for healthcare workers will be 
needed. An increase in the workforce for ART provision 
will be critical as expanded numbers of people come 
forward for testing and referral services. Th is workforce 
should be drawn from the pool of current healthcare 
providers, augmented by community workers trained to 
provide treatment support and to monitor and evaluate 
aspects of the project. Stable patients on ART, requiring 
lower levels of care and monitoring, could be managed 
through alternative healthcare sites but with increased 
community workforce support. Laboratory support would 
have to be in place. Th e community workforce will be 
essential for tracking patients on ART, ensuring that 
adherence with ART is documented, reducing the number 
of defaulters, and monitoring migration in and out of the 
community.
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Monitoring and evaluation
When scaling up testing and early treatment, data 
manage ment will be essential. Biometric ﬁ ngerprinting 
could be used to prevent duplication of testing and to 
monitor patients. An integrated data system should be 
used to track patients on ART, monitor testing rates, HIV 
status, referrals for ART, pharmacy pick ups, laboratory 
results, and follow-up care. To preserve conﬁ dentiality, 
electronic ID cards may be used to reduce the risk of 
increased stigmatization; when the card is read 
electronically, the person’s status will be known only to 
the healthcare providers. Th e data should be used not 
only to answer the key research questions, but also to 
provide feedback to the community.
Th e most important outcomes to be measured will be 
acceptance of testing, agreement to start treatment, 
compliance, side eﬀ ects, viral load suppression, viral 
rebound, drug resistance, residual transmission between 
discordant couples, risk compensation, and the impact 
on opportunistic infections and mortality.
Planned and ongoing studies
Interest in using TasP has grown rapidly in the past two 
years [45] and a number of studies are in various stages of 
planning and development. Some involve viral load 
testing which, although not widely available in most 
developing countries, could be used to better target those 
who are at greatest risk of dying and are most likely to 
transmit the virus.
Th e Mochudi project in Botswana [46] will combine 
community-wide HIV prevention, including male circum-
cision, with a “test-and-treat” strategy. HIV-positive 
people with CD4+ cell counts above 250 cells/mm3 will be 
oﬀ ered three-drug ART if their viral loads are greater 
than 50,000 RNA copies/mL, while those with CD4+ cell 
counts below 250 cells/mm3 will be referred for ART 
through the public programme. HIV incidence and 
molecular methods to elucidate transmission pathways 
will be used to evaluate the impact of the trial, which will 
last for ﬁ ve years.
In the iTLC (International Testing and Linkage to Care) 
study, the HIV Prevention Trials Network and Family 
Health International are planning a three-arm, multi-site 
community randomized trial [46] comparing: a) the local 
standard of care; b) enhanced HIV testing and linkage to 
care with ART initiation based on the local standard of 
care; and c) enhanced testing and linkage to care with 
ART provided to all HIV-infected patients who have 
plasma HIV-1 RNA greater than 50,000 copies/mL.
Th e TLC (Test and Link to Care) study, also co-
ordinated by the HIV Prevention Trials Network, will 
determine the feasibility of a community-based, en-
hanced test and link-to-care strategy in Washington DC 
and Th e Bronx, New York [47]. Th is study will focus on 
expanded HIV testing, linkage to care, viral load sup-
pression, prevention for positives, and patient and 
provider surveys.
Th e PopART (Population Eﬀ ects of Anti-Retroviral 
Th erapy) trial is being developed by scientists based in 
the United Kingdom and in Africa to see if the 
widespread use of ART for all adults testing HIV positive 
could substantially reduce HIV transmission [48].
TTEA (Test and Treat to End AIDS) is a feasibility 
study of annual testing and immediate treatment in the 
Western Cape Province of South Africa, being planned 
by scientists in South Africa, the United States and 
Canada [46,49].
ANRS (Agence Nationale de Recherches sur le SIDA) 
12249-TasP is planning a pilot study of TasP which, if 
successful, will be developed into a community 
randomized controlled trial. It will be done by scientists 
from the University of Bordeaux, the Hôpitaux Univer-
sitaires de Genève, and the Africa Centre for Health and 
Population Studies in South Africa [50].
Stop AIDS Now!, a Dutch non-governmental organiza-
tion, with support from the South African Centre for 
Epidemiological Modelling and Analysis (SACEMA) and 
the Clinton Health Access Initiative (CHAI), has been 
granted money from the Dutch Lottery Fund to start a 
project in Swaziland to: ensure that, within three years, 
there is universal access to treatment under current 
UNAIDS/WHO guidelines; evaluate the impact of 
achieving this; and carry out a proof-of-concept study for 
treatment-centred prevention [51].
Th e SEARCH collaboration is performing pilot studies 
in preparation for a community randomized study to 
evaluate health, economic and education outcomes of 
universal ART (test and treat at all CD4 cell counts) in 
three east African countries: Uganda, Kenya and 
Tanzania (Diane Havlir, personal communication).
Th e NIH (National Institutes of Health, USA) has 
awarded grants to 12 research teams as part of a ﬁ ve-year 
eﬀ ort to study HIV prevention, testing and treatment for 
individuals in jails and prisons. Th e programme aims to 
link inmates to care – and, if appropriate, antiretroviral 
therapy – while incarcerated, with continued follow up 
and support after they are released and return to their 
communities [52].
Conclusions
TasP oﬀ ers the chance of signiﬁ cantly reducing HIV 
transmission and eventually bringing the HIV epidemic 
to an end. Th e World Health Organization previously 
recommended starting ART for all people with CD4+ cell 
counts below 200 cells/mm3 [53], but, in 2010, this was 
raised to 350 cells/mm3 [5]. Th e United States Depart-
ment of Health and Human Services and the Inter-
national AIDS Society-USA guidelines now recommend 
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consideration of ART even when the CD4+ cell count is 
greater than 500/mm3 [54], while in San Francisco the 
public health system recommends that all HIV-positive 
people should be oﬀ ered immediate access to ART [56]. 
Modelling studies show that each of these increases, 
200  cells/mm3 to 350 cells/mm3 to 500 cells/mm3 to 
immediate treatment, will further reduce the incidence of 
HIV, as well as of AIDS-related tuberculosis [17].
A number of studies to investigate the impact of TasP 
are being planned or have started, and these will provide 
important and valuable information for the design of 
more rigorous trials. Th ey will also inform public health 
policy regarding the management of HIV, regardless of 
whether or not they show that TasP could stop trans-
mission. However, an ambitious programme of TasP 
would, in its initial phases, require signiﬁ cant increases 
in funding, and it will be important to investigate the 
ﬁ nancial demands and economic impact of TasP. If ways 
can be found to ensure that those carrying out these 
projects remain in close contact and exchange ideas, 
plans and results, the work will proceed more rapidly and 
eﬃ  ciently.
In parallel with feasibility studies, it will be important 
to develop cost-beneﬁ t analyses to compare the current 
HIV/AIDS strategy with one involving much earlier 
treat ment, and, indeed, to examine the impact of target-
ing TasP at those in greatest need and at those who, for 
behavioural or biological reasons, are most likely to 
infect others. Costs will include direct healthcare 
investments needed to implement the strategy, 
including the cost of drugs, infrastructure, logistics and 
human resources. Beneﬁ ts will include the reduction in 
new infections, including opportunistic infections, and 
deaths, reduced demands placed on the healthcare 
system, and the beneﬁ ts to society of keeping young 
adults alive.
Th e present situation, in which increasing numbers of 
HIV-positive people need to be maintained on expensive 
drugs, which must be taken regularly and for life, is not 
sustainable. Ways must be found to signiﬁ cantly reduce, 
and perhaps even eliminate, transmission. Where possible, 
TasP should be backed up and supported by other 
methods of prevention, including the promotion of 
behaviour change, making condoms available and acces-
sible, providing male circumcision services, promoting 
needle exchange programmes, couples counselling, 
addressing the needs of pregnant women, providing ART 
to people suﬀ ering from other opportunistic infections, 
especially tuberculosis, and providing pre-exposure 
prophylaxis to those at very high risk. However, much 
still needs to be learned and there will be many obstacles 
to overcome. But if the work starts now, we might hope 
to see signiﬁ cant and rapid reductions in transmission 
within the next decade.
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